Cite
HARVARD Citation
Girard, N. et al. (2015). ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. Expert review of anticancer therapy. 15 (2), pp. 225-233. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Girard, N. et al. (2015). ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. Expert review of anticancer therapy. 15 (2), pp. 225-233. [Online].